Improvement in absolute Psoriasis Area and Severity Index score through 3 years of continuous treatment with guselkumab in the VOYAGE 1 trial

Background: VOYAGE 1 is a phase 3, randomized, double-blind, placebo/active comparator-controlled trial comparing guselkumab (GUS), a fully human monoclonal antibody targeting interleukin-23, with adalimumab (ADA) in the treatment of patients with psoriasis. We assessed long-term responses based on absolute Psoriasis Area and Severity Index (PASI) scores through 3 years of continuous GUS treatment in VOYAGE 1.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research